Nasdaq · CIK 0002130606
OBX Obsidian Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Aug 5, 2026.
In brief
Obsidian Therapeutics, Inc. (OBX) has 6 SEC Form 4 filings on file from 6 insiders, the latest filed on Aug 5, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Obsidian Therapeutics, Inc., scored.
Transactions
Every row filed, 6 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Peter Barrett director | AGrant or award Stock Option (Right to Buy)derivative | +37,653 | $0.00 | $0 | 37,653 | Aug 5, 2026 |
| Aug 3, 2026 | Maria Fardis director | AGrant or award Stock Option (Right to Buy)derivative | +37,653 | $0.00 | $0 | 37,653 | Aug 5, 2026 |
| Aug 3, 2026 | Heidi Hagen director | AGrant or award Stock Option (Right to Buy)derivative | +37,653 | $0.00 | $0 | 37,653 | Aug 5, 2026 |
| Aug 3, 2026 | Madan Jagasia Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +37,653 | $0.00 | $0 | 37,653 | Aug 5, 2026 |
| Aug 3, 2026 | Matthew Norkunas director | AGrant or award Stock Option (Right to Buy)derivative | +37,653 | $0.00 | $0 | 37,653 | Aug 5, 2026 |
| Aug 3, 2026 | Robert W. Ross director | AGrant or award Stock Option (Right to Buy)derivative | +37,653 | $0.00 | $0 | 37,653 | Aug 5, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Peter Barrettdirector
- Maria Fardisdirector
- Heidi Hagendirector
- Madan JagasiaChief Executive Officer
- Matthew Norkunascfo, officer, director
- Robert W. Rossdirector
Questions about OBX
Answered from the filings on this page, as of the latest one.
Are insiders buying OBX?
No. In the last 90 days no insider at Obsidian Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade OBX on the open market?
No open-market trade has been scored at Obsidian Therapeutics, Inc.. The latest Form 4 on file was filed on Aug 5, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Obsidian Therapeutics, Inc.?
6 people have filed a Form 4 at Obsidian Therapeutics, Inc., among them Peter Barrett (director), Maria Fardis (director), Heidi Hagen (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.